PharmaCorp Rx Inc.
PCRX.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.92M | 6.96M | 4.17M | 1.02M | 213.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.92M | 6.96M | 4.17M | 1.02M | 213.00K |
| Cost of Revenue | 6.03M | 4.26M | 2.60M | 646.10K | 140.90K |
| Gross Profit | 3.89M | 2.70M | 1.57M | 376.70K | 72.10K |
| SG&A Expenses | 4.08M | 3.21M | 2.53M | 1.91M | 940.20K |
| Depreciation & Amortization | 459.30K | 339.40K | 208.80K | 72.00K | 16.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.56M | 7.80M | 5.34M | 2.63M | 1.10M |
| Operating Income | -641.90K | -845.00K | -1.17M | -1.61M | -884.50K |
| Income Before Tax | -188.30K | -458.00K | -860.50K | -1.46M | -818.60K |
| Income Tax Expenses | 113.40K | -1.00K | -76.10K | 400.00 | -200.00 |
| Earnings from Continuing Operations | -0.30 | -0.46 | -0.78 | -1.46 | -0.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 19.70K | 17.30K | 25.90K | 100.00 | -1.20K |
| Net Income | -282.10K | -439.90K | -758.70K | -1.46M | -819.70K |
| EBIT | -641.90K | -845.00K | -1.17M | -1.61M | -884.50K |
| EBITDA | -249.00K | -564.00K | -838.00K | -1.21M | -433.90K |
| EPS Basic | 0.00 | -0.01 | -0.02 | -0.03 | -0.03 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.02 | -0.02 |
| EPS Diluted | 0.00 | -0.01 | -0.02 | -0.03 | -0.03 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 463.29M | 401.64M | 306.62M | 209.36M | 116.48M |
| Average Diluted Shares Outstanding | 463.29M | 401.64M | 306.62M | 209.36M | 116.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |